Investors Purchase High Volume of Intersect ENT Call Options (NASDAQ:XENT)

Intersect ENT Inc (NASDAQ:XENT) saw some unusual options trading on Thursday. Stock traders purchased 2,233 call options on the company. This represents an increase of approximately 834% compared to the average daily volume of 239 call options.

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Intersect ENT by 5.1% during the third quarter. State Street Corp now owns 726,772 shares of the medical equipment provider’s stock valued at $12,362,000 after acquiring an additional 35,130 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of Intersect ENT in the third quarter valued at $1,917,000. Quadrant Capital Group LLC purchased a new stake in shares of Intersect ENT in the third quarter valued at $36,000. California State Teachers Retirement System boosted its stake in shares of Intersect ENT by 2.5% during the third quarter. California State Teachers Retirement System now owns 48,481 shares of the medical equipment provider’s stock valued at $825,000 after acquiring an additional 1,193 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Intersect ENT by 21.1% during the third quarter. California Public Employees Retirement System now owns 45,300 shares of the medical equipment provider’s stock valued at $771,000 after acquiring an additional 7,900 shares during the last quarter. Hedge funds and other institutional investors own 96.87% of the company’s stock.

Several analysts have recently commented on the company. BidaskClub raised Intersect ENT from a “hold” rating to a “buy” rating in a research report on Thursday, January 16th. Piper Jaffray Companies set a $21.00 price target on Intersect ENT and gave the company a “hold” rating in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. increased their price objective on Intersect ENT from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $27.25.

NASDAQ:XENT opened at $28.76 on Friday. Intersect ENT has a 12 month low of $14.61 and a 12 month high of $35.87. The stock has a market capitalization of $852.48 million, a price-to-earnings ratio of -22.47 and a beta of 0.91. The firm has a fifty day simple moving average of $25.24 and a two-hundred day simple moving average of $20.40.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

See Also: Trade War

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply